Mirum Pharmaceuticals (MIRM) Scheduled to Post Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, March 8th. Analysts expect Mirum Pharmaceuticals to post earnings of ($0.98) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Mirum Pharmaceuticals Stock Up 1.3 %

MIRM opened at $23.86 on Monday. Mirum Pharmaceuticals has a 52-week low of $17.32 and a 52-week high of $30.55. The company has a market cap of $879.72 million, a P/E ratio of -21.30 and a beta of 1.33. The firm’s 50-day moving average price is $22.11 and its 200-day moving average price is $21.54.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Polar Capital Holdings Plc purchased a new stake in Mirum Pharmaceuticals in the 1st quarter worth approximately $21,441,000. State Street Corp boosted its position in Mirum Pharmaceuticals by 258.5% in the 3rd quarter. State Street Corp now owns 988,962 shares of the company’s stock worth $20,778,000 after purchasing an additional 713,095 shares in the last quarter. BlackRock Inc. boosted its position in Mirum Pharmaceuticals by 25.3% in the 3rd quarter. BlackRock Inc. now owns 1,749,349 shares of the company’s stock worth $36,754,000 after purchasing an additional 353,337 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Mirum Pharmaceuticals in the 4th quarter worth approximately $6,620,000. Finally, Vanguard Group Inc. boosted its position in Mirum Pharmaceuticals by 26.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,244,925 shares of the company’s stock worth $26,155,000 after purchasing an additional 261,950 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. HC Wainwright cut their price objective on shares of Mirum Pharmaceuticals from $69.00 to $61.00 and set a “buy” rating on the stock in a report on Wednesday, February 15th. SVB Leerink dropped their target price on Mirum Pharmaceuticals from $50.00 to $39.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 10th. Citigroup dropped their target price on Mirum Pharmaceuticals from $38.00 to $34.00 and set a “buy” rating on the stock in a research report on Thursday, November 10th. Raymond James dropped their target price on Mirum Pharmaceuticals from $88.00 to $84.00 and set a “strong-buy” rating on the stock in a research report on Tuesday, January 10th. Finally, JPMorgan Chase & Co. dropped their target price on Mirum Pharmaceuticals to $30.00 in a research report on Monday, November 28th.

About Mirum Pharmaceuticals

(Get Rating)

Mirum Pharmaceuticals, Inc is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O’Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.